FDA Advisory Committee Votes Against Compounding Emideltide, Citing Safety and Efficacy Concerns
核心洞察
FDA advisers voted 7-6 with 1 abstention against allowing compounding pharmacies to produce emideltide (搜索), a delta sleep-inducing peptide, marking the first such rejection in the two-day review of seven peptides.
Committee members cited low-quality efficacy evidence, poor characterization of the bulk drug substance, and the existence of approved medical therapies as reasons for the "no" vote.
The FDA's own scientists recommended against reclassifying all seven peptides under review, stating insufficient data on safety risks, clinical benefits, and manufacturing processes.
A Food and Drug Administration advisory committee voted against reclassifying emideltide (搜索) for compounding on Friday, marking the first time during the two-day review that advisers rejected a peptide under consideration. The vote was 6 in favor and 7 against, with 1 abstention.
Emideltide (搜索), also known as the delta sleep-inducing peptide, has been promoted for addressing insomnia (搜索), narcolepsy (搜索), and opioid withdrawal. Unlike other peptides reviewed by the committee, some clinical studies have assessed its effectiveness — but all were conducted in the 1980s and 1990s, and the FDA described the results as "inconclusive and at best preliminary."
"I voted 'no' primarily for low-quality evidence around efficacy, the poor characterization of the bulk drug substance, and the fact that there are approved medical therapies for social uses," said Todd Durham, an FDA adviser and executive at the Foundation Fighting Blindness.
Broader Peptide Review Underway
The advisory committee convened for two days to evaluate whether seven peptides — which have gained popularity in wellness circles — should be permitted for compounding by pharmacies in the United States. On Thursday, the advisers largely voted in favor of allowing four peptides: BPC-157, KPV, TB-500, and MOTS-C.
The remaining two peptides under discussion Friday are epitalon and semax, both originally discovered and synthesized in Russia. Semax is the only peptide among the seven that holds formal regulatory approval in any country; it is cleared for use in Russia to treat stroke and optic-nerve conditions.
FDA Scientists Recommended Against Reclassification
The FDA's own scientists recommended against reclassifying all seven peptides, citing insufficient data regarding safety risks, clinical benefits, and manufacturing processes. A "yes" vote from the advisory committee does not constitute FDA approval — it simply means compounding pharmacies can legally produce these products.
"Consumers will interpret reclassification as FDA approval," Adriane Fugh-Berman, director of a watchdog organization that studies pharmaceutical marketing, told the committee on Thursday. "Most of these peptides will harm patients."
The Compounding Landscape
The peptide trend gained momentum alongside the mainstreaming of biohacking and increased demand for compounded GLP-1 medications during shortages. In 2023, the FDA moved to restrict production of 14 compounded peptides, which advocates say pushed some consumers toward gray-market sources, including overseas laboratories.
"The 2023 restrictions did not raise the standards, they abandoned them," Ricardo Rosselló, the former governor of Puerto Rico, a drug-manufacturing hub, told the committee. "They sent patients to markets where those standards don't exist."
The final determination now rests with FDA leadership, which is not bound by the committee's recommendation but traditionally follows it.